跳至主要内容
临床试验/JPRN-UMIN000006952
JPRN-UMIN000006952已完成3 期

A randomised comparison of safety and efficacy of triple therapy for 12 weeks, followed by 12 or 36 additional weeks of peginterferon alfa 2b and ribavirin in HCV patients - Study of 12 or 36 additional weeks of peginterferon alfa 2b and ribavirin

Hiroshima liver study group0 个研究点目标入组 230 人开始时间: 2011年12月26日最近更新:

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
230

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 70years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)Transient response to prior treatment 2)Patients receiving shosaiko-to 3)Autoimmune hepatitis 4)History of hypersensitivity to PEG-IFN alpha-2b and telaprevir 5)History of hypersensitivity to biological products such as vaccine 6)Decompenstated liver cirrhosis 7)HCC, malignat tumor 8)With or with a history of severe psychosis such as severe depression, suicidal ideation or attempt, etc. 9)Pregnant or lactating women and women who may be pregnant 10)Judged by investigator not to be appropriate for inclusion in this study

研究者

发起方
Hiroshima liver study group

相似试验